Lead Sponsor

Camurus AB

Age

40 - 85 years

Sex

MALE

Healthy Volunteers

No

•Men ≥40 and ≤85 years of age
•Histological or cytological proven adenocarcinoma of the prostate requiring hormone therapy
•Life expectancy over 12 months
•World Health Organisation/ The Eastern Cooperative Oncology Group (WHO/ECOG) performance status of 0, 1 or 2
•Adequate and stable renal function
•Adequate and stable hepatic function

•Evidence of brain metastasis, spinal cord compression, or urinary tract obstruction
•Serum Testosterone levels below 150 ng/dL at Screening visit
•Medical or radiological prostate cancer treatments within 2 months prior to the Screening visit
•Surgical treatment of prostate cancer within 2 weeks prior to the Screening visit
•Prior orchiectomy, hypophysectomy, or adrenalectomy
•Prior use of LHRH agonists within 12 months prior to the Screening visit and during the study

Related studies

NCT07580196 · Prostate Cancer

NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer

NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer